Activity

Mikayla Schneider - December 09 VIEW RECORDING - 32 mins (No highlights): https://fathom.video/share/1L7Vtj-VfKBW8BJTmQCPzqtcHywtGwMg --- 0:00 - Andrew Hartmann (UTAK Laboratories) Good, how are you? Doing all right. We're in a heat wave here in Missouri. I don't know what it's like in Wisconsin, but we're a balmy 55 right now. Oh, no, freezing cold and snowing all day. 0:11 - Mikayla Schneider (slh.wisc.edu) Oh, back at home office, it's in the 70s right now. 0:16 - Andrew Hartmann (UTAK Laboratories) Wow, that sounds really nice. Yeah, we were on a call with a guy in New York. He's like, it's one here right now. Yeah, it's pretty cold here, yeah. I relocated back to Missouri like two years ago from Southern California and still don't like the cold, just... 0:33 - Mikayla Schneider (slh.wisc.edu) Yeah, it's not fun, but that's all right. 0:38 - Andrew Hartmann (UTAK Laboratories) You get through it, you know, you have those couple of weeks in the spring and in the fall where it's just lovely before the hot, humid summer and... Yeah. Are we waiting for Kristen or is it just us? Yep, there we go. Sorry. 0:58 - Mikayla Schneider (slh.wisc.edu) Sorry. No, you're good. Oh, good. Hi. That's a nice painting you guys have in the background. 1:05 - Andrew Hartmann (UTAK Laboratories) I like your conference room. Oh, thank you. 1:09 - Mikayla Schneider (slh.wisc.edu) That has been here, I think, as long as I have. Oh, wow. 1:13 - Andrew Hartmann (UTAK Laboratories) I was using photos of my cats as my background, and so my company was so kind to make me some of these digital backgrounds. I think it was their way of hinting my cats aren't a priority. Yeah. Well, they'd be distracting. 1:26 - Mikayla Schneider (slh.wisc.edu) You know, I would be paying more attention to the photos of your cats. 1:33 - Andrew Hartmann (UTAK Laboratories) Uh-oh. I think my screen just froze up. Can you hear me? Hello, hello? If you can hear me, I cannot hear you. Oh, there we go. We're back now, I think. I'm back. 1:54 - Mikayla Schneider (slh.wisc.edu) We're back. Can I hear you? You can hear me? 1:56 - Andrew Hartmann (UTAK Laboratories) Yes. All right. Not sure what happened there. All good. Appreciate you guys making some time to connect. Looks like you had some interest in Custom QC. Yes. 2:10 - Mikayla Schneider (slh.wisc.edu) So we met with Raleigh a couple months ago. She was our contact point. Did that switch over now? Yeah. So Raleigh is no longer with us, but for anything you guys need, I'm more than happy to be your point of contact. 2:28 - Andrew Hartmann (UTAK Laboratories) Perfect. Okay. Awesome. So, yeah. 2:31 - Mikayla Schneider (slh.wisc.edu) So one of the things that we have been interested in looking at is a external QC for buprenorphine and norbuprenorphine. Okay. With those, our biggest, like, issue, concern, I guess, is stability with those. Have you guys made? Do those before further places? Quite a bit, yeah. Okay. 3:06 - Andrew Hartmann (UTAK Laboratories) What matrix are you guys looking in? 3:10 - Mikayla Schneider (slh.wisc.edu) It would be blood. 3:20 - Andrew Hartmann (UTAK Laboratories) Bear with me one second. Let me just see if I can find another quote. I'm a little trouble pulling up something live time, but I'm pretty sure we might have stability data on that one. If not, I know that we're making it for other customers and they're not having issues. Sometimes our lack of stability data is just to make an FDA claim, so it doesn't necessarily mean it won't work. Okay. I know that we're for sure doing BUP and NORBUP for quite a few customers. Okay. We're absolutely right. Let's pray. Okay, perfect. 4:03 - Mikayla Schneider (slh.wisc.edu) Would you have a preference as far as a frozen product or a lyophilized product? What have we traditionally used? I would say when we have concerns over stability, we go frozen. Yeah. Okay. Rather than the lyophilized. I know the last time we had UTAK make any type of control with buprenorphine in it for us, we ended up, and I'm not saying we have to go this far, but we ended up with kind of a hybrid type thing where we had, it was a combo control, had like six analytes in it. And we had the other five analytes frozen in the blood, and then you sent us small aliquots of buprenorphine stock that we added to it when we bought it right before we used it. Okay. Because I know that was – we had trouble with that one. But I will honestly say I think a lot of the trouble was our test, not just, you know, the instability or the UTAK product. That is kind of our go-to when we do see a customer having a stability issue. 5:18 - Andrew Hartmann (UTAK Laboratories) We do that quite often with, like, Delta 9 and some of the other analytes that have sort of known stability issues. So I can have our team kind of review and, you know, look at our other products that we're making and come back and say, you know, hey, we're pretty confident this is going to work in Frozen or, you know, let's stick with that two-part option. Okay. 5:37 - Mikayla Schneider (slh.wisc.edu) I guess from a standpoint of our chemists having to do multiple things with it, if you don't think stability is an issue in regular Frozen with the two analytes, I'd say that is a better place to start. Yeah, definitely agree. 5:54 - Andrew Hartmann (UTAK Laboratories) We like to stick Frozen form or freeze-dried. Getting into that two-part gets a little bit murky. But just depending on – Depending on the analytes and stuff, like volatiles we find work really well in the two parts, THCs and a couple of those work really well in the two parts, so I'll have our quoting team kind of do a deep dive and, you know, flag for stability and see what we can come up with. As far as bill size per vial, you know, how much material are you guys using, like, per day or per test? 6:24 - Mikayla Schneider (slh.wisc.edu) Oh, that's a new quant, and they've changed the entire extraction method. Yeah, is it going to? It's half-mil quant now, so I would assume they would use a half a mil of whatever the UTAK, but it doesn't get run very often. Right. It's going to be somewhat low volume, but fill volume? Maybe a mil, and if they wanted to run it straight and then times two if they're using a half. 7:03 - Andrew Hartmann (UTAK Laboratories) Now, you guys were using a half a mil and you want to get two runs out of it, I'd say let's do a 1.2 ml fill size, just because if we put one mil in a vial, you'll never actually get, like, one mil out just because of vial loss, or if you want to do a single-use vial, we could do, like, a 0.7 mil, and then it would just be, like, a thaw and use for each test. 7:28 - Mikayla Schneider (slh.wisc.edu) They probably would want the thaw and use, because they're only going to use it once, or are they going to do a straight and a spike? Well, no, they won't do a spike, but if they wanted to do the QC at, like, a straight and a times two concentration. Okay. I, yeah, I guess I'm not sure what they are looking at. Yeah, although maybe they haven't talked to me about that. Yeah. You know what? Maybe just going with, like, a 0.7 fill, because it's, like, we have internal QC too, and the internal, you know, the internal QC, they can run at multiple concentrations. So we just want, like, one external. We don't, I don't think we need to do, like, where they get two different things out of each one. Yeah. 8:23 - Andrew Hartmann (UTAK Laboratories) Your external QC, guys are, or sorry, internal, you're making that yourself, and it's just whole blood, you're spiking it in. What kind of stability are you seeing with that? 8:36 - Mikayla Schneider (slh.wisc.edu) It's, it's hard to really say, because the quant hasn't been going super well. From what I've, I haven't been really privy to any of the meetings. Yeah. So, know, from a historical standpoint, I'll tell you this. When I, now, Michaela is taking over the QA responsibilities, but long ago, when we first When started our bup test, I would make a control, and I would freeze little aliquots of whole blood, right, with buprenorphine and norbuprenorphine in it. It was not stable. Um, we, I don't know, six months maybe before we started to drop off. So what we do now is we have a separately prepared stock solution for our QC, and at the time of the test, they pipette the stock and then add the blank blood to it at that time. Gotcha. 9:39 - Andrew Hartmann (UTAK Laboratories) Would you want to see us do, like, a methanol mixture that you guys are then aliquoting in? Do you want to try and hold blood? We kind of have some variability that we can work with you on that. 9:52 - Mikayla Schneider (slh.wisc.edu) I mean, if the methanol is more stable, that could work. Um, if Bye. 10:00 - Andrew Hartmann (UTAK Laboratories) If we're doing methanol, you know, like, just to be transparent, our minimum order size, no matter what we do, is going to be 50 ml. So, like, if we're doing 0.7 ml aliquots, you know, that's going to be over 50 vials. Just kind of based off of what you've seen in stability in the past, we normally expect our product to be kind of similar to that. It might almost be better to target, like, a higher concentration of methanol, and then you could use the UTAK methanol to dilute down to make multiple levels of your internal QC. That way, you're just buying one product from us, but then there's multiple uses. You we could look into both, too, if you want to look into a method. 10:38 - Mikayla Schneider (slh.wisc.edu) Yeah, because I think with 50 aliquots, our concern would be stability because we won't go through them very quickly. It's not a clock that gets run very often, so I think that's the biggest thing with that. Yeah. might be easier to have us do a 50 ml. Right, because if you make individual aliquots frozen in blood, that we thaw one and we just pipette it, traditional stability is like two and a half years on those, right? 11:17 - Andrew Hartmann (UTAK Laboratories) Usually for our frozen products, it's 18 months, but it can be analyte-specific, so our quoting team will kind of review and, you know, tell you what we have data-wise. 11:27 - Mikayla Schneider (slh.wisc.edu) So in 18 months, we'd only go through 12 to maybe 15 of those 50 vials, so, yeah. Which, then, so at 50 mil, at least with the methanol, that one we might be able to go through a little bit more, maybe, or maybe not, I don't know. 11:57 - Andrew Hartmann (UTAK Laboratories) Yeah. I'm kind of an options guy. If you're all right with it, I'd like to. We'll look into both and just see, you know, how it prices out, what our stability data is, and then you guys can take a look at it and decide, you know, what's going to be the best fit for you. 12:10 - Mikayla Schneider (slh.wisc.edu) That would be great, I think, if you could provide that kind of stuff for Mikayla, and she can take it back to the analysts to figure out what they want to try. Yeah, perfect. 12:22 - Andrew Hartmann (UTAK Laboratories) So volume, I'm hearing, we're not going to be exceeding the 50 ml, so we'll quote minimum. Is there a target budget or a price point you're trying to reach for this material? That has not been shared with me. 12:37 - Mikayla Schneider (slh.wisc.edu) That's Dan's department, usually. Well, yeah, I mean, I'm trying to remember what the other QC we get from UTEP costs. Are they all lyophilized? I think currently everything we're using is lyophilized. Yeah, I haven't been shown any of those. Yeah. Do we usually – I want to say, like, in my head there, you know, maybe if we get a lyophilized and it's five mils or whatever, that it's usually $40 a vial or something like that. You know, as long as it's not so terribly out there, it would be something that we could evaluate. Okay. 13:28 - Andrew Hartmann (UTAK Laboratories) Let me pull up your MDMA control. 13:31 - Mikayla Schneider (slh.wisc.edu) Yeah, that, I think, was the most recent one that we had you develop for us. 13:39 - Andrew Hartmann (UTAK Laboratories) That one's at about $96 per vial, if my rough math is correct. Is it? Okay. 13:46 - Mikayla Schneider (slh.wisc.edu) That's more than I remember. But that's okay. I mean, we like it. We're using it, so. They just updated my CRM, and it's totally different than it was yesterday, and I'm not sure where to find a copy of that quote yet. 13:59 - Andrew Hartmann (UTAK Laboratories) So, I'll it. Oh, okay. So, I'll do A little digging, but I'll just kind of put that there's no defined budget, but obviously we'll try to keep it down as low as possible. Our team just uses that to try to back into, like, design and stuff. If there's, like, a, you know, hey, for whatever reason, this is going to make it more expensive. We should, you know, transition to this. 14:15 - Mikayla Schneider (slh.wisc.edu) Yeah, I think the trick is that the MDMA and math control, we run that test. I mean, we don't run the MDMA very often, but we run math a couple times every week. Yeah. So the difference is, you know, if you give us a bottle of the math control, we're going to use it up. We're not going to waste any of that, you know, that we've rehydrated and whatever. That's not true of potentially what we might get with the Bionor Buu. Okay. 14:52 - Andrew Hartmann (UTAK Laboratories) And then concentration-wise, I would need to know what concentration you want if we're making it in whole blood. I would also need to know, like, what concentration you'd want to see if we're making a stock solution. Did they share that with you? 15:08 - Mikayla Schneider (slh.wisc.edu) It would have been in the email, but I don't think so. I would pick, in-house controls are at, what, 1 in 10, I think. So, you want to pick, like, if you're making it in blood, I'd say pick 5 nanograms per mil. Or 2 nanograms per mil. Just so it's, you know, somewhere in the middle of what we're targeting. Sure. We could do either, 5 or 2. 15:39 - Andrew Hartmann (UTAK Laboratories) So, what would your preference be? 15:44 - Mikayla Schneider (slh.wisc.edu) Cost-wise, would 2 be more cost-efficient? If that's small of a concentration, it's not really going to make a difference. Yeah, because the big cost comes from the time and the vials and the... The lyophilization process, if we were doing that, or the aliquoting out process, those kinds of things, right? 16:06 - Andrew Hartmann (UTAK Laboratories) Yeah, so when we're chasing after costs, the most cost effective is always the highest volume. Because the way we price our products, a good majority of is what we call fixed costs. So regardless if we're making 50 mil or 5 liters, you know, we've got to pay somebody to do a quality final batch review. We've got to pay somebody to create the labeling templates. We've got to do the manufacturing paperwork. You know, there's a lot of fixed costs that doesn't change no matter what we're making. And then you have the incremental cost, which is, you know, a little bit more of the blood, a little bit more of the drugs. So at a minimum order size, pricing tends to be a little bit on the higher side. But if you guys have like high volume test panels and things like that, you know, the pricing substantially comes down on like a per vial price when you, you know, start upping that volume. Because we're able to spread those fixed costs over a larger variety, know, larger number of vials. Yeah. 17:00 - Mikayla Schneider (slh.wisc.edu) Um, so then probably the 5 nanograms per mil so that it's right in the middle because they'll have a low and they'll have a high QC within 20% on either side. So having maybe a middle one might be nice. Yeah. 17:18 - Andrew Hartmann (UTAK Laboratories) And then methanol, what would you like as far as concentration on that one? I'd have to do some math. You said your high QC is 10? 17:28 - Mikayla Schneider (slh.wisc.edu) I think so. I mean, the current method was, you know, they are revalidating right now. 17:38 - Andrew Hartmann (UTAK Laboratories) Maybe we do 100 and that way the top level QC is like a 1 in 10 mixture of methanol blood and then everything else is below that. That's usually kind of the threshold we see most customers trying to stick under is like 10% methanol in a product and in the rest matrix. Okay. 17:55 - Mikayla Schneider (slh.wisc.edu) Yeah, that seems reasonable if you did 100 nanograms per mil. Okay. Okay. Okay. Okay. Okay. 18:04 - Andrew Hartmann (UTAK Laboratories) And then would you want the same fill size for a methanol product as you have for the whole blood, or would you prefer something different there? 18:16 - Mikayla Schneider (slh.wisc.edu) So I want to understand you're not talking about sending us a bottle. You are talking about sending us individual aliquots of methanol. 18:25 - Andrew Hartmann (UTAK Laboratories) So that's what we recommend just to prevent, like, where we see a lot of issues come up is like the freeze-thaw cycling, even though methanol doesn't freeze. It's the bringing it out, bringing it up to room temperature, putting it back in, top coming off, top going back on. We like to see that minimized, especially when there is stability issues. So we would kind of, I think, want to target, but you guys are only doing this test every now and again. Like, let's target a fill size that would be like per test. Okay. 18:55 - Mikayla Schneider (slh.wisc.edu) Half a mil? Half a mil should be fine, because then if anything happens. It depends where they need to redo it. They don't have to completely pull out a new one for that day, because things do happen where they may miss pipette into a wrong, you know, well, and then they need to just restart the plate itself, but they're going to keep going with everything that they have out for the day, so that should help prevent, because I don't think that they would use more than a half a mil. No, no, for pipetting-wise, but that would give them enough room to not have to wait for another one to thaw. Oh, warm, yeah, yeah. Perfect. 19:43 - Andrew Hartmann (UTAK Laboratories) So we're going to pull you two options. We'll do one option in whole blood at a 7 ml fill size, and we'll target 5 nanograms per mil for both bup and norbup, and then we'll do a methanol option at a 0.5 ml fill size, and we'll target 100. for the buprenorphine, one. Does that sound right? I think so. And then I'll have our team kind of do a deep dive on stability here for us, just because that does seem to be a concern on your end. So I'll see what we can come up with as far as data or, you if they have any other ideas of, you know, what might make it work better. But even the two-part, typically it's one part blood, one part methanol. So I think if stability is going to be a concern, probably leading towards that methanol might be a better option. Although I do recognize that's a little bit more work on your team to do. So we'll see what they say after it gets through quoting, and then we'll reconnect and go from there. Okay, that sounds good. 20:42 - Mikayla Schneider (slh.wisc.edu) I don't think we have anything else at the moment. Awesome. I had a couple of questions for you guys, if you don't mind. 20:50 - Andrew Hartmann (UTAK Laboratories) Raleigh may have covered some of this for you, but so it might be duplicate. So feel free just to tell me that you've already answered it. But what I wanted to check in and just see how that new MDM The AQC is working out for you guys. It seems to be working well. 21:05 - Mikayla Schneider (slh.wisc.edu) We haven't had any reported issues at the very least. No, those quants are, like, very solid. Unless we have instrument issues, the quant almost always works. Unless you know when you have the instrument problem, which is what a controller is made to do. 21:21 - Andrew Hartmann (UTAK Laboratories) Exactly. Yep. 21:23 - Mikayla Schneider (slh.wisc.edu) We should, let us just think about it, we should see how much is left and how soon we need to order again. Yeah. Any room for improvement on that product? 21:33 - Andrew Hartmann (UTAK Laboratories) Anything design-wise or feature-wise that you'd want to see different the next time around? 21:40 - Mikayla Schneider (slh.wisc.edu) I can't think of it. Yeah, I think we'd have to ask, like, Alan. Yeah. Okay. Yeah, we'd have to get back to you on that. 21:50 - Andrew Hartmann (UTAK Laboratories) I saw a little while ago you guys got a sample of our whole blood, and I never saw an order come through for the blood. I was just kind of curious, you know, how that worked out for you. And... were doing... ... ... 22:00 - Mikayla Schneider (slh.wisc.edu) Yeah, so we purposely had gotten that as an evaluation to see if we could use that as our Blank Matrix for our cocaine quant, because we were having issues with interference on the cocaine peak with blood that we get from the Red Cross. And we got the UTAK blood in, and that also had the interference that we were looking for, or that we were trying to get rid of. So it really didn't make sense for us to try to use that as a Blank Matrix, because it didn't solve our problem. 22:50 - Andrew Hartmann (UTAK Laboratories) Interesting. Those kind of, like, interference issues are always so curious to me, because, you know, you send it to another lab, and they say, oh, it works just fine, and, like, figuring out, like, what is happening. With this product and this, you know. 23:02 - Mikayla Schneider (slh.wisc.edu) Yeah, and it truly doesn't really make a whole lot of sense. We haven't totally figured out what happened because, like, literally the first order we got in 2024, that's when this interferon popped up. And it's been around ever since then, and we can't identify why. Do you see it in your patient samples? 23:25 - Andrew Hartmann (UTAK Laboratories) Occasionally, but not really. 23:27 - Mikayla Schneider (slh.wisc.edu) Not to the extent that we see it. And, like, blood matrices. Interesting. 23:33 - Andrew Hartmann (UTAK Laboratories) If you'd be interested in taking a deeper look, we do have an option to kind of work with people that have sort of more sensitive or picky tests. We call it single donor. So when we have our stock product, it's a pool of blood. Usually, you know, at least three, but often, like, 20 or 30 people kind of pooled together into one lot. We do have the ability, though, to send you samples from individual donor bags. And then you can test, you know, five or 10 of these samples. So you figure out which ones work, which ones don't, and then you can buy either, you know, whatever that donor had donated, or you can say like, hey, these three samples all work, pool those three together and then give me, you know, X amount of mils of that. So if you're ever in a situation where you're looking for, you know, a blood provider, we do have ways that we can work with you to try to ensure that, you know, your final pool is going to work. 24:24 - Mikayla Schneider (slh.wisc.edu) Yeah, right now we're also developing a new quant on an LC for Coke. So we're hoping that once we move to that, then this will go away. So we can reevaluate if it doesn't seem like that's going well and quickly enough and we can see. But right now like it's been holding stable enough where some we've identified some lots that are better than others and don't interfere quite as much. So we're kind of at a stable holding ground. Perfect. 25:03 - Andrew Hartmann (UTAK Laboratories) And then I saw in the past, you guys used to order a drugs of abuse whole blood control from us. Has that been replaced by that MDMA control? Or do you know if you discontinued that for any reason? It looked like 2022 was the last time I saw that one ordered. Yeah, that was before my time. 25:18 - Mikayla Schneider (slh.wisc.edu) Yeah, so we had, we used that in our cocaine quant and our meth, amfet, amfet quant, and we decided ultimately that we were not going to have an external QC in our cocaine quant, but then we wanted to keep having MDMA and meth and amfet. So I know we haven't had MDMA that long, but we just kind of switched from using that QC, which used to be a DOA type in the. The coke and the meth quant, now it's being used in the meth and the MDMA quant. We just kind of, you know, switched a little bit. 26:08 - Andrew Hartmann (UTAK Laboratories) Hold out what you wanted and put it back together. Yeah. What is it that motivates you to want to use an external QC versus making it in-house? 26:21 - Mikayla Schneider (slh.wisc.edu) Best practice, really. I mean, it's important to try to have an external when we can. Um, sometimes it's not, we're not able to due to financial constraints or due to just the ability of stability, all those things, but we'd like to have them if possible, but it's fine. Do have... No, I mean, I, I have always taken the stance that if we can have both, that's best. Um, especially for things that are, you know, illicit substances, Wisconsin has a zero tolerance law. I, I, I, Thank For, you know, things like Methamphet, MDMA, Delta-9, cocaine is in there. And so, you know, that's kind of where we target is can we get both external and internal controls for those drugs for our quantitative procedures anyway. We quit having external QC in the cocaine because we were running into stability issues where, you know, the coke would drop off and the BE would increase. Now, we never did look at a frozen aliquots instead of the lyophilized for that. We did used to, when we would lyophilize it, or when, sorry, when we would rehydrate it, we would then keep it in the freezer and just, you know, freeze and thaw it for the two or three runs that it would get used in. But, you know, we know that as it sits there, the cocaine is just converting to BE. We see that happen as well, yeah. 28:12 - Andrew Hartmann (UTAK Laboratories) One tip for any of our lyophilized products, once you've reconstituted it, we don't recommend doing freeze-thaw cycles. But what we do recommend is aliquoting it into smaller vials, refreezing those smaller vials, and then that way you can just pull it out and thaw. We see that, you know, oftentimes that one thaw cycle, everything is A-OK. The more freeze-thaw cycles we see, the more we start to see stability problems kind of creep in. So, you know, if you are making aliquots of the MDMA or anything like that, we would definitely recommend, you know, aliquoting out, freezing, and then just pulling them out as you need, you know, each aliquot. 28:52 - Mikayla Schneider (slh.wisc.edu) We haven't had a problem with the meth, MFET, MDMA, MDA. Yeah, are all pretty stable. 28:59 - Andrew Hartmann (UTAK Laboratories) those But... Cocaine in whole blood is notorious for that. Yeah, we've seen that happen in many of our products. 29:07 - Mikayla Schneider (slh.wisc.edu) That's a valid point, though, that, you know, I don't think we had ever even considered, like, well, maybe once we rehydrate, we should aliquot it out ourselves into single-use, you know, vials. But we do know when we left it in the refrigerator, we had more degradation, more conversion from Coke to the E than when we froze it. 29:31 - Andrew Hartmann (UTAK Laboratories) It seems even that blood in the vial still is trying to have a party in your refrigerator. If you had to give UTAK a rating 1 through 10, what would you give us and why? Let's see. 29:49 - Mikayla Schneider (slh.wisc.edu) That's, that's easy. I haven't really been around too long. Can I give you multiple grades? Sure. I give you, like, an, uh, 10 on... Being willing to talk to us and being willing to work with us on things, I'd give you maybe only a 7 on how things really work in our lab. And it's only as low as a 7 because we are dealing with unstable analytes, which we don't hold against UTAK. But, you know, we all have to struggle with how to make our Buprenorphine in our QC stay consistent over the time we want to use it, you know. So it's, so I'm, I mean, I guess since I gave you a 7 on a 10, I am holding it against you, but it's not personal because I know we all have to deal with that. But, but everyone at UTAK has always been very willing to talk to us, very willing to try to figure these things out.annnettable.comannettable.comannettable No, that's great feedback. 31:02 - Andrew Hartmann (UTAK Laboratories) You know, appreciate it. That's it as far as my questions for survey and all that go. I'll work on these quotes, probably give us around two to three business days, and then once I have them, I'll send you out a link that we can just have like a quick little 15-minute quote recap, and I'll get some stability information from our team and kind of see if they can give me an indication of, you know, what we're expecting to actually see. So I'll bring that to the table when we reconnect and we'll go from there. Okay, sounds good. 31:31 - Mikayla Schneider (slh.wisc.edu) Awesome. 31:32 - Andrew Hartmann (UTAK Laboratories) If anything ever comes up, you guys have my contact info. There's a Calendly link in my signature. So feel free to book a time with me anytime you guys want to chat. Sounds good. All right. 31:41 - Mikayla Schneider (slh.wisc.edu) Thank you so much. Awesome. Have a good one. 31:44 - Andrew Hartmann (UTAK Laboratories) Stay warm.